Lupin has announced that its US subsidiary has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC). The company has accomplished this under a strategic licensing agreement with New Jersey-based respiratory research and development company InspiRX. The agreement grants Lupin exclusive rights to promote, distribute and market InspiraChamber VHC in the USA.

Developed by InspiRX, the all new InspiraChamber VHC is a device that has been designed to enhance delivery of aerosol therapies. The InspiraChamber VHC is intended to be used by patients who are under the care or treatment of a physician or licensed healthcare professional. The device is intended to be used by these patients to administer aerosolized medication from most pressurized Metered Dose Inhalers (pMDIs).

The InspiraChamber VHC launch strengthens Lupin existing brand portfolio in the United States. Lupin's current brands sales force will promote InspiraChamber in the US market and the product will be marketed along with other Lupin brands, including Suprax, Alinia for Oral suspension, Locoid Lotion and Antara.

"We are very excited with the addition of InspiraChamber VHC to our brand business portfolio. The launch demonstrates Lupin's commitment to grow its brand franchise in the US and bring meaningful products to patients in the country. The launch also heralds Lupin's entry into the larger US inhalation and related markets," said Ms Vinita Gupta, CEO, Lupin.

Mr Michael Amato, CEO of InspiRx said, "The agreement enables the commercialization of InspiraChamber in the US. Furthermore, and given Lupin's brand equity within the US Pediatric community, the launch ensures that the product reaches children, infants and toddlers, an age demographic which we feel needs a product like InspiraChamber; a VHC that ensures better and more effective drug delivery."